VRTX – Vertex Pharmaceuticals Incorporated
VRTX — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
1.63
Margin Of Safety %
15
Put/Call OI Ratio
0.76
EPS Next Q Diff
0.08
EPS Last/This Y
3.7
EPS This/Next Y
2.79
Price
431.86
Target Price
553.68
Analyst Recom
1.58
Performance Q
-3.77
Upside
-21.9%
Beta
0.37
Ticker: VRTX
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-03-09 | VRTX | 460.73 | 0.74 | 0.34 | 48783 |
| 2026-03-10 | VRTX | 499.08 | 0.71 | 0.88 | 50592 |
| 2026-03-11 | VRTX | 492.24 | 0.75 | 1.54 | 52247 |
| 2026-03-12 | VRTX | 477.98 | 0.78 | 1.09 | 53672 |
| 2026-03-13 | VRTX | 478.13 | 0.78 | 1.03 | 53672 |
| 2026-03-17 | VRTX | 462.48 | 0.74 | 1.15 | 51061 |
| 2026-03-18 | VRTX | 451.64 | 0.72 | 1.17 | 51743 |
| 2026-03-19 | VRTX | 458.02 | 0.72 | 1.23 | 51889 |
| 2026-03-20 | VRTX | 454.04 | 0.71 | 7.20 | 52561 |
| 2026-03-23 | VRTX | 451.23 | 0.92 | 1.86 | 48022 |
| 2026-03-24 | VRTX | 448.72 | 0.90 | 0.48 | 48458 |
| 2026-03-25 | VRTX | 455.18 | 0.88 | 3.01 | 49492 |
| 2026-03-26 | VRTX | 453.84 | 0.78 | 3.68 | 47112 |
| 2026-03-27 | VRTX | 434.07 | 0.79 | 1.57 | 47577 |
| 2026-03-30 | VRTX | 443.27 | 0.71 | 0.89 | 42508 |
| 2026-03-31 | VRTX | 446.46 | 0.71 | 0.34 | 44146 |
| 2026-04-01 | VRTX | 446.95 | 0.73 | 0.81 | 43906 |
| 2026-04-02 | VRTX | 438.67 | 0.74 | 1.21 | 44647 |
| 2026-04-06 | VRTX | 435.05 | 0.76 | 0.70 | 42987 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-03-09 | VRTX | 460.81 | 8.4 | 1013.2 | 19.17 |
| 2026-03-10 | VRTX | 499.14 | 8.4 | 1445.9 | 19.17 |
| 2026-03-11 | VRTX | 492.40 | 8.4 | 881.5 | 19.17 |
| 2026-03-12 | VRTX | 478.06 | 8.7 | 790.9 | 19.19 |
| 2026-03-13 | VRTX | 469.11 | 8.7 | 850.4 | 19.19 |
| 2026-03-17 | VRTX | 462.57 | 8.9 | 916.3 | 19.19 |
| 2026-03-18 | VRTX | 451.62 | 8.9 | 823.1 | 19.19 |
| 2026-03-19 | VRTX | 457.91 | 8.9 | 750.7 | 19.19 |
| 2026-03-20 | VRTX | 454.00 | 8.9 | 624.0 | 19.19 |
| 2026-03-23 | VRTX | 451.20 | 8.9 | 638.8 | 19.19 |
| 2026-03-24 | VRTX | 448.67 | 8.9 | 641.5 | 19.16 |
| 2026-03-25 | VRTX | 455.11 | 8.9 | 753.3 | 19.16 |
| 2026-03-26 | VRTX | 453.92 | 8.9 | 643.7 | 19.16 |
| 2026-03-27 | VRTX | 432.97 | 8.9 | 403.2 | 19.16 |
| 2026-03-30 | VRTX | 443.25 | 8.9 | 786.8 | 19.16 |
| 2026-03-31 | VRTX | 446.46 | 8.9 | 697.7 | 19.16 |
| 2026-04-01 | VRTX | 447.14 | 8.9 | 664.0 | 19.16 |
| 2026-04-02 | VRTX | 438.72 | 8.9 | 550.8 | 19.16 |
| 2026-04-06 | VRTX | 434.32 | 8.9 | 601.0 | 19.16 |
| 2026-04-07 | VRTX | 431.86 | 8.9 | 625.2 | 19.16 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-03-09 | VRTX | -27.05 | 0.01 | 1.76 |
| 2026-03-10 | VRTX | -27.05 | 0.01 | 1.76 |
| 2026-03-11 | VRTX | -27.05 | 0.01 | 1.75 |
| 2026-03-12 | VRTX | -27.05 | 0.01 | 1.75 |
| 2026-03-13 | VRTX | -27.22 | 0.01 | 1.75 |
| 2026-03-17 | VRTX | -27.37 | 0.01 | 1.75 |
| 2026-03-18 | VRTX | -27.37 | 0.01 | 1.75 |
| 2026-03-19 | VRTX | -27.37 | 0.01 | 1.75 |
| 2026-03-20 | VRTX | -27.37 | 0.01 | 1.75 |
| 2026-03-23 | VRTX | -27.37 | 0.02 | 1.75 |
| 2026-03-24 | VRTX | -27.37 | 0.02 | 1.75 |
| 2026-03-25 | VRTX | -27.37 | 0.02 | 1.63 |
| 2026-03-26 | VRTX | -27.37 | 0.02 | 1.63 |
| 2026-03-27 | VRTX | -27.37 | 0.02 | 1.63 |
| 2026-03-30 | VRTX | -27.37 | 0.02 | 1.63 |
| 2026-03-31 | VRTX | -27.51 | 0.02 | 1.63 |
| 2026-04-01 | VRTX | -27.51 | 0.02 | 1.63 |
| 2026-04-02 | VRTX | -27.51 | 0.02 | 1.63 |
| 2026-04-06 | VRTX | -27.53 | -0.05 | 1.63 |
| 2026-04-07 | VRTX | -27.53 | -0.05 | 1.63 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
4.65
Avg. EPS Est. Current Quarter
4.42
Avg. EPS Est. Next Quarter
4.73
Insider Transactions
-27.53
Institutional Transactions
-0.05
Beta
0.37
Average Sales Estimate Current Quarter
3055
Average Sales Estimate Next Quarter
3214
Fair Value
495.33
Quality Score
99
Growth Score
83
Sentiment Score
45
Actual DrawDown %
16.9
Max Drawdown 5-Year %
-29.1
Target Price
553.68
P/E
28.16
Forward P/E
19.44
PEG
1.77
P/S
9.09
P/B
5.88
P/Free Cash Flow
34.35
EPS
15.33
Average EPS Est. Cur. Y
19.16
EPS Next Y. (Est.)
21.95
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
32.74
Relative Volume
0.68
Return on Equity vs Sector %
-6.3
Return on Equity vs Industry %
10.3
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.04
EBIT Estimation
625.2
◆
VRTX
Healthcare
$431.86
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
37.5
Range 1M
6.3%
Sup Dist
0.1%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
5%
EPS NY
15%
52W%
45.9%
Long-Term Value
Quality companies, undervalued
WATCH
🟡 HOLD
+16% upside
Upside
+16%
Quality
99
MoS
15%
Vertex Pharmaceuticals IncorporSector: Healthcare
Industry: Biotechnology
Employees: 6400
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
VRTX
Latest News
—
Caricamento notizie per VRTX…
stock quote shares VRTX – Vertex Pharmaceuticals Incorporated Stock Price stock today
news today VRTX – Vertex Pharmaceuticals Incorporated stock forecast ,stock prediction 2023 2024 2025
marketwatch VRTX – Vertex Pharmaceuticals Incorporated yahoo finance google finance
stock history VRTX – Vertex Pharmaceuticals Incorporated invest stock market
stock prices VRTX premarket after hours
ticker VRTX fair value insiders trading